Sickle Cell Disease


Errant Gene Therapeutics (“EGT”) asks European Authorities to Re-examine the Approval Process of Zynteglo, While US Litigation Moves Forward

Picking up on the ongoing “Family Man” saga, in New York Court, EGT claims that Zynteglo, the Bluebird Bio product for Thalassemia, created Clonal Dominance. EGT alleges that Bluebird Bio assisted Memorial Sloan Kettering in orchestrating the sabotage of EGT’s product...

Pin It on Pinterest